Plateforme de Pharmacocinétique, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.
Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal, Quebec, Canada.
J Pharm Biomed Anal. 2019 Oct 25;175:112766. doi: 10.1016/j.jpba.2019.07.014. Epub 2019 Jul 12.
Ondansetron is a highly selective 5-hydroxytryptamine type 3 (5-HT) receptor antagonist that is well tolerated in the clinic. Pre-clinical studies in rats have shown interesting effects of small doses of ondansetron on cognition, behavioural sensitisation and epilepsy. However, the pharmacokinetic profile at a very low dose has not been reported, possibly because currently, there are no published analytical methods capable of quantifying trace levels of ondansetron in plasma or brain. The objective of this study was to develop and validate a highly sensitive HPLC-MS/MS assay capable of quantifying ondansetron in rat plasma and rat brain homogenate following a low subcutaneous administration of 1.0 μg/kg. Ondansetron was extracted by protein precipitation with methanol containing labeled ondansetron. The chromatography was performed on a Thermo Scientific Aquasil C18 analytical column (100 x 2.1 mm I.D., 5 μm) operating at 40 °C. The mobile phase consisted of acetonitrile and 10 mM ammonium formate pH 3 at a ratio of 30:70, respectively. The flow rate was fixed at 300 μL/min and ondansetron and the internal standard were both eluted at 2.3 min. A linear (1/x) relationship was used to perform the calibration over an analytical range from 20.0 - 10,000 pg/mL in plasma and from 2.00 to 1000 pg/mL in rat brain homogenate. The inter-batch precision and accuracy ranged from 3.7 to 4.7% and from 0.7 to 10.9% in rat plasma, respectively. The inter-batch precision and accuracy observed in rat brain was 4.5 to 6.4% and -5.1 to 4.9% respectively. The method met all requirements and the assay was suitable for the determination of the pharmacokinetic profile following a subcutaneous dose of 1.0 μg/kg body weight (BW) in rats.
昂丹司琼是一种高度选择性的 5-羟色胺 3(5-HT3)受体拮抗剂,在临床上具有良好的耐受性。在大鼠的临床前研究中,小剂量昂丹司琼对认知、行为敏化和癫痫有有趣的影响。然而,极低剂量的药代动力学特征尚未报道,可能是因为目前没有发表的分析方法能够定量检测血浆或脑组织中痕量的昂丹司琼。本研究的目的是开发和验证一种高度敏感的 HPLC-MS/MS 分析方法,能够在大鼠皮下给予 1.0μg/kg 后定量检测血浆和大鼠脑匀浆中的昂丹司琼。昂丹司琼通过含标记昂丹司琼的甲醇沉淀蛋白进行提取。色谱在 Thermo Scientific Aquasil C18 分析柱(100×2.1mm I.D.,5μm)上进行,柱温为 40°C。流动相由乙腈和 10mM 甲酸铵 pH 3 组成,比例为 30:70。流速固定在 300μL/min,昂丹司琼和内标均在 2.3min 洗脱。在血浆中分析范围为 20.0-10,000pg/mL,在大鼠脑匀浆中分析范围为 2.00-1000pg/mL 时,采用 1/x 线性关系进行校准。批内精密度和准确度在大鼠血浆中分别为 3.7-4.7%和 0.7-10.9%。在大鼠脑中观察到的批内精密度和准确度分别为 4.5-6.4%和-5.1-4.9%。该方法符合所有要求,适用于测定大鼠皮下给予 1.0μg/kg 体重(BW)后药代动力学特征。